Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Architecture and Design
Arts
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest
Geosciences
History
Industrial Chemistry
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies
Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Cart
Home
Journals
Acta Pharmaceutica
Volume 74 (2024): Issue 1 (March 2024)
Open Access
A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality
Nem Kumar Jain
Nem Kumar Jain
,
Mukul Tailang
Mukul Tailang
,
Neelaveni Thangavel
Neelaveni Thangavel
,
Hafiz A. Makeen
Hafiz A. Makeen
,
Mohammed Albratty
Mohammed Albratty
,
Asim Najmi
Asim Najmi
,
Hassan Ahmad Alhazmi
Hassan Ahmad Alhazmi
,
Khalid Zoghebi
Khalid Zoghebi
,
Muthumanickam Alagusundaram
Muthumanickam Alagusundaram
,
Hemant Kumar Jain
Hemant Kumar Jain
and
Balakumar Chandrasekaran
Balakumar Chandrasekaran
| Mar 30, 2024
Acta Pharmaceutica
Volume 74 (2024): Issue 1 (March 2024)
About this article
Previous Article
Next Article
Abstract
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Published Online:
Mar 30, 2024
Page range:
1 - 36
Accepted:
Nov 09, 2023
DOI:
https://doi.org/10.2478/acph-2024-0005
Keywords
FGFR
,
tyrosine kinase inhibitors
,
FDA approval
,
erdafitinib
,
infigratinib
,
pemigatinib
,
futibatinib
© 2024 Nem Kumar Jain et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Nem Kumar Jain
School of Pharmacy, ITM University Gwalior
India
School of Studies in Pharmaceutical Sciences, Jiwaji University Gwalior
India
Mukul Tailang
School of Studies in Pharmaceutical Sciences, Jiwaji University Gwalior
India
Neelaveni Thangavel
Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Jazan University
Saudi Arabia
Hafiz A. Makeen
Pharmacy Practice Research Unit Department of Clinical Pharmacy, College of Pharmacy, Jazan University
Saudi Arabia
Mohammed Albratty
Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Jazan University
Saudi Arabia
Asim Najmi
Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Jazan University
Saudi Arabia
Hassan Ahmad Alhazmi
Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Jazan University
Saudi Arabia
Khalid Zoghebi
Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Jazan University
Saudi Arabia
Muthumanickam Alagusundaram
School of Pharmacy, ITM University Gwalior
India
Hemant Kumar Jain
Department of General Medicine Government Medical College,
Datia, India
Balakumar Chandrasekaran
Faculty of Pharmacy, Philadelphia University
Amman, Jordan